Suslina Z A, Ionova V G, Nikitenko N Iu, Maksimova M Iu
Ter Arkh. 1993;65(9):53-6.
Clinical efficacy of tiklid in a dose 500 mg/day and its action on platelet vascular hemostasis were evaluated in 24 patients with cerebrovascular diseases. A 15-day tiklid course promoted a regress in some subjective symptoms (headache, vertigo, walking instability, photopsias, etc.), the objective neurological status being unchanged. Tiklid had a positive influence on some rheological parameters and platelet vascular hemostasis. ADP-induced platelet aggregation, blood fibrinogen levels got reduced. The platelets sensitivity to antiaggregation agent PgI2 in vitro arose. Antiaggregation potential of the vascular wall returned to normal in 33% of patients with initially low or inverse response.
对24例脑血管疾病患者评估了剂量为500毫克/天的抵克立得的临床疗效及其对血小板血管止血的作用。为期15天的抵克立得疗程使一些主观症状（头痛、眩晕、行走不稳、闪光幻觉等）有所减轻，而客观神经学状态未改变。抵克立得对一些流变学参数和血小板血管止血有积极影响。ADP诱导的血小板聚集、血纤维蛋白原水平降低。体外血小板对抗聚集剂前列环素（PgI2）的敏感性提高。在最初反应低或呈反向反应的患者中，33%的患者血管壁的抗聚集潜能恢复正常。
